Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review

被引:12
作者
Guo, Li [1 ]
Chen, Xiao-xiang [1 ]
Gu, Yue-ying [1 ]
Zou, He-jian [2 ]
Ye, Shuang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, Shanghai 200001, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Div Rheumatol, Shanghai 200040, Peoples R China
关键词
Imatinib; Systemic sclerosis; GROWTH-FACTOR; MESYLATE; DISEASE;
D O I
10.1007/s10067-012-2032-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis (SSc) is a progressive fibrotic disorder with no legitimate effective treatment. Several clinical trials had investigated imatinib mesylate with a target dose of 400 similar to 600 mg/day on SSc, and the efficacy is controversial with a generally poor tolerability. We herein reported six female Chinese patients with SSc administered with low-dose imatinib (200 mg/day) for a median of 23 months (10 similar to 30 months). Patients displayed a decreased modified Rodman skin scores (mRSS) by a mean of 6.29 points after 6 months of treatment. Three patients who completed 2 years of treatment achieved a reduction of mRSS by 8, 18, and 30.5 points, respectively. Pulmonary function was improved or stabilized in two patients with interstitial lung disease. Severe gastrointestinal involvement in one patient was attenuated in terms of discontinuation of total parenteral nutrition and restoration of the serum albumin level. Imatinib was well-tolerated in general, although there were two severe adverse events: a bone fracture and a cerebral hemorrhage in two individuals. Both the adverse events were probably not directly related to imatinib and were recovered uneventfully. Our limited data, along with the review of the literature, suggested that low-dose imatinib might be effective and better tolerated in severe SSc that deserves further study.
引用
收藏
页码:1395 / 1400
页数:6
相关论文
共 19 条
[1]   PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
不详 .
ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590
[2]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[3]  
Baroni SS, 2006, NEW ENGL J MED, V354, P2667
[4]  
Chung L, 2010, AM COLL RHEUM ANN SC
[5]   Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis [J].
Chung, Lorinda ;
Fiorentino, David F. ;
BenBarak, Maya J. ;
Adler, Adam S. ;
Mariano, Melissa M. ;
Paniagua, Ricardo T. ;
Milano, Ausra ;
Connolly, M. Kari ;
Ratiner, Boris D. ;
Wiskocil, Robert L. ;
Whitfield, Michael L. ;
Chang, Howard Y. ;
Robinson, William H. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (02) :584-591
[6]  
CLEMENTS P, 1995, J RHEUMATOL, V22, P1281
[7]  
Distler O, 2010, AM COLL RHEUM ANN SC
[8]   Imatinib mesylate in the treatment of chronic myeloid leukaemia [J].
Druker, BJ .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (06) :963-971
[9]   Mechanisms of Disease: Scleroderma. [J].
Gabrielli, Armando ;
Avvedimento, Enrico V. ;
Krieg, Thomas .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (19) :1989-2003
[10]   A One-Year, Phase I/IIa, Open-Label Pilot Trial of Imatinib Mesylate in the Treatment of Systemic Sclerosis-Associated Active Interstitial Lung Disease [J].
Khanna, Dinesh ;
Saggar, Rajeev ;
Mayes, Maureen D. ;
Abtin, Fereidoun ;
Clements, Philip J. ;
Maranian, Paul ;
Assassi, Shervin ;
Saggar, Rajan ;
Singh, Ram R. ;
Furst, Daniel E. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (11) :3540-3546